Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-21
2011-06-21
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C424S001690
Reexamination Certificate
active
07964555
ABSTRACT:
A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4485045 (1984-11-01), Regen
patent: 4496689 (1985-01-01), Mitra
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5530109 (1996-06-01), Goodearl et al.
patent: 5586110 (1996-12-01), Nakaki et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5667780 (1997-09-01), Ho et al.
patent: 5714385 (1998-02-01), Mather et al.
patent: 5716930 (1998-02-01), Goodearl et al.
patent: 5721139 (1998-02-01), Mather et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5856110 (1999-01-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6033660 (2000-03-01), Mather et al.
patent: 6087323 (2000-07-01), Gwynne et al.
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 6121415 (2000-09-01), Godowski et al.
patent: 6136558 (2000-10-01), Ballinger et al.
patent: 6156728 (2000-12-01), Gao et al.
patent: 6162641 (2000-12-01), Goldman et al.
patent: 6169070 (2001-01-01), Chen et al.
patent: 6252051 (2001-06-01), Godowski et al.
patent: 6387638 (2002-05-01), Ballinger et al.
patent: 6399746 (2002-06-01), Vandlen et al.
patent: 6444642 (2002-09-01), Sklar et al.
patent: 6446242 (2002-09-01), Lien et al.
patent: 6593290 (2003-07-01), Gao et al.
patent: 6635249 (2003-10-01), Marchionni et al.
patent: 6750196 (2004-06-01), Reh et al.
patent: 7226907 (2007-06-01), Zhou
patent: 7612164 (2009-11-01), Zhou
patent: 2006/0019888 (2006-01-01), Zhou
patent: 2006/0194734 (2006-08-01), Zhou
patent: 2006/0199767 (2006-09-01), Zhou
patent: 2007/0129296 (2007-06-01), Zhou
patent: 2007/0190127 (2007-08-01), Zhou
patent: 2007/0213264 (2007-09-01), Zhou
patent: 2007/0264254 (2007-11-01), Zhou
patent: 2008/0260713 (2008-10-01), Zhou
patent: 2009/0156488 (2009-06-01), Zhou
patent: 2009/0203595 (2009-08-01), Zhou
patent: 68278/94 (1994-12-01), None
patent: 1138785 (2004-02-01), None
patent: 1138785 (2004-02-01), None
patent: 1498656 (2004-05-01), None
patent: 1715926 (2006-01-01), None
patent: 1743005 (2006-03-01), None
patent: 1743006 (2006-03-01), None
patent: 3218121 (1983-11-01), None
patent: 0 036 676 (1981-09-01), None
patent: 0 052 322 (1982-05-01), None
patent: 0 058 481 (1982-08-01), None
patent: 0 088 046 (1983-09-01), None
patent: 0 102 324 (1984-03-01), None
patent: 0 143 949 (1985-06-01), None
patent: 0 133 988 (1995-03-01), None
patent: 0 647 449 (1995-04-01), None
patent: 0 142 641 (1995-05-01), None
patent: 60007934 (1985-01-01), None
patent: WO 89/01489 (1989-02-01), None
patent: WO 92/18627 (1992-10-01), None
patent: WO 94/00140 (1994-01-01), None
patent: WO 94/26298 (1994-04-01), None
patent: WO 94/26298 (1994-05-01), None
patent: WO 94/26298 (1994-11-01), None
patent: WO 95/32724 (1995-12-01), None
patent: WO 96/15812 (1996-05-01), None
patent: WO 97/09425 (1997-03-01), None
patent: WO 99/18976 (1999-04-01), None
patent: WO 00/37095 (2000-06-01), None
patent: WO 03/099300 (2003-12-01), None
patent: WO 03/099320 (2003-12-01), None
patent: WO 03/099321 (2003-12-01), None
Balligand et al. Cardiac endothelium and tissue growth. Progress in Cardiovascular Diseases (Jan./Feb.), 1997; 3(4):351-360.
Balligand, et al., “Cardiac endothelium and tissue growth,” Prog Cardiovasc Dis. Jan.-Feb. 1997; 39(4):351-360.
Chien, et al., “Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response,” FASEB J. Dec. 1991; 5(15):3037-3046.
Colucci, et al., “Pathphysiology of heart failure,” Chapter 13 inHeart Diseases: A textbook of cardiovascular medicine, Braunwald, ed., Saunders, Philadelphia. 1996; 5:394-420.
Dias, et al., “The molecular basis of skeletal muscle differentiation,” Semin Diagn Pathol. Feb. 1994; 11(1):3-14.
Eppstein, et al., “Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor,” Proc Natl Acad Sci U S A. Jun. 1985; 82(11):3688-3692.
Florini-Jr., et al., “Stimulation of myogenic differentiation by a neuregulin, glial growth factor 2,” J Biol Chem. May 31, 1996; 271(22):12699-12702.
Holmes, et al., “Identification of heregulin, a specific activator of p185erbB2,” Science. May 22, 1992; 256(5060):1205-1210.
Hwang, et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: a kinetic study,” Proc Natl Acad Sci U S A. Jul. 1980; 77(7):4030-4034.
Langer, et al., “Biocompatibility of polymeric delivery systems for macromolecules,” J Biomed Mater Res. Mar. 1981; 15(2):267-277.
Parker, et al., “p53-independent expression of p21Cip 1 in muscle and other terminally differentiating cells,” Science. Feb. 17, 1995; 267(5200):1024-1027.
Physicians' Desk Reference. Medical Economics Data Production Co., Montvale, NJ. 1994; pp. 2314-2320.
Rumyantsev, “Interrelations of the proliferation and differentiation processes during cardiac myogenesis and regeneration,” Int Rev Cytol. 1977; 51:186-273.
Sidman, et al., “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid,” Biopolymers. Jan. 1983; 22(1):547-556.
Simpson, et al., “Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines,” Circ Res. Dec. 1982; 51(6):787-801.
Zhao, et al., “Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes,” J Biol Chem. Apr. 24, 1998; 273(17):10261-10269.
Zhao, et al., “Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes,” Development. May 1998; 125(10):1899-1907.
Zhou, et al., “Retinoid-dependent pathways suppress myocardial cell hypertrophy,” Proc Natl Acad Sci U S A. Aug. 1, 1995; 92(16):7391-7395.
Gray H., Gray's Anatomy: The Anatomical Basis of Medicine and Surgery, 1995, Ed. Williams et al., Churchill Livingstone, Edinburgh, pp. 264-254, 298-310 and 739-771.
International Search Report for International Application No. PCT/AU99/01137, Mar. 10, 2000.
Liu et al., “Neuregulin-1/ErbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy,” J Am Coll Cardiol., 2006, 48(7):1438-1447.
Liu et al., “Effects of neuregulin on Rhesus monkey heart failure induced by rapid pacing,” Sichuan Da Xue Xue Bao Yi Xue Ban., 2009, 40(1):93-96 (in Chinese with English Abstract).
Olson et al., “Regulation of muscle transcription by the MyoD family The heart of the matter,” Circ Res. 1993, 72(1):1-6.
Stevenson et al., “Optimizing therapy for complex or refractory heart failure: a management algorithm,” Am Heart J. 1998, 135(6 Pt 2 Su):S293-S309.
Partial European Search Report for European Application No. 08020020.7, Jan. 7, 2009.
U.S. Appl. No. 61/118,563, filed Nov. 28, 2008, Zhou.
U.S. Appl. No. 61/118,566, filed Nov. 28, 2008, Zhou.
Schaper et al., “Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy,” Circulation. 1991, 83(2):504-514.
Hein et al , “Altered expression of titin and
Audet Maury
Jones Day
Zensun ( Shanghai ) Sci & Tech Co., Ltd.
LandOfFree
Cardiac muscle function and manipulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac muscle function and manipulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac muscle function and manipulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2730575